Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three Devices Gain Medicare Add-Ons, Including Boston Sci's New TAVR Protector

Executive Summary

The US Medicare agency granted inpatient new-technology add-on payments for Boston Scientific's newly acquired cerebral protection system for TAVR, Respicardia's neurostimulator for sleep apnea and Procept BioRobotics' novel resection system for benign prostatic hyperplasia. The highly selective bonus payments typically help drive adoption for the chosen new technologies.

Advertisement

Related Content

Market Intel: Martin Leon's TAVR Technology Tour Of The Future
Procept's Aquablation BPH Therapy Gets Boost From UK NICE Guidance
NICE Endorses Sutureless Aortic Valves While LivaNova Reaches Study Milestone
CMS Finalizes Spending Per Beneficiary Quality Measure Over MDMA Objections
Boston Scientific Gulps Down Claret After Cryterion, In Double-Whammy July
Procept BioRobotics Believes Aquablation Could Dominate BPH Treatment…If It Gets Coverage
CMS Could Streamline Coverage For Breakthrough Medtech Under House Proposal
Medicare Bonus Payments: CMS Plans To End Three, But Considers Seven New-Tech Add-On Payments For FY 2019
Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT123083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel